RxDoctor Payments Data

Lane Carlin, MD

Neurology · Fort Myers, FLNPI 1033112263

Payments from drug & device makers

$12,516in general payments, 2019–2025

Across 629 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Amgen$883
  • Novartis$716
  • GE HealthCare$687
  • Sanofi$490
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$570%
  • Food & beverage$12,45199%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)111$1,835
UCB, Inc.39$1,063
Amgen(2 entities)43$883
Novartis42$716
GE HealthCare38$687
Sanofi20$490
Acadia Pharmaceuticals Inc36$482
SK Life Science, Inc.9$386
Biogen20$345
Genentech USA, Inc.19$317
Argenx US, Inc.13$315
AstraZeneca(2 entities)13$289
Lundbeck LLC14$288
Octapharma USA, Inc.8$285
Sunovion Pharmaceuticals Inc.13$272
Lilly USA, LLC18$269
Bristol Myers Squibb11$232
EMD Serono, Inc.14$219
Neurocrine Biosciences, Inc.12$201
Jazz Pharmaceuticals Inc.4$196
Pfizer10$162
Sumitomo Pharma America, Inc.3$162
Alnylam Pharmaceuticals Inc.7$161
Eisai Inc.7$158
CSL Behring6$149
Acorda Therapeutics, Inc7$147
Catalyst Pharmaceuticals, Inc.3$140
Abbott2$134
Teva Pharmaceuticals USA, Inc.7$120
Scilex Pharmaceuticals Inc.5$114
Merz Pharmaceuticals, LLC5$101
Adamas Pharmaceuticals, Inc.5$92
Otsuka America Pharmaceutical, Inc.4$76
Biohaven Pharmaceutical Holding Company Ltd.4$73
Biohaven Pharmaceuticals, Inc.4$66
Amneal Pharmaceuticals LLC4$59
Supernus Pharmaceuticals, Inc.4$56
Revance Therapeutics, Inc.2$53
E.r. Squibb & Sons, L.L.C.3$49
Avanir Pharmaceuticals, Inc.4$49
Neurelis, Inc.3$43
Kyowa Kirin, Inc.2$43
Johnson & Johnson2$43
Medtronic2$42
Upsher-smith Laboratories LLC3$41
Sanofi-aventis U.S. LLC2$41
Grifols USA, LLC2$39
Almatica Pharma LLC2$38
Avion Pharmaceuticals2$33
MDD US Operations, LLC2$29
Insightec,inc2$28
Greenwich Biosciences, Inc.2$26
Springworks Therapeutics, Inc.1$25
Takeda Pharmaceuticals U.S.A., Inc.1$24
Corium, LLC1$20
Ipsen Biopharmaceuticals, Inc1$20
Sandoz1$16
Servier Pharmaceuticals LLC1$16
Impel Pharmaceuticals Inc.1$15
Kedrion Biopharma, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,516 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$925,432
Medicare patients
868
Services billed
35,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl20$60,483
QuliptaAtogepant16$24,831
XcopriCenobamate15$22,693
NuedextaDextromethorphan Hbr/Quinidine13$20,493
Adderall XrDextroamphetamine/Amphetamine15$7,169
Levetiracetam143$6,891
Carbamazepine ErCarbamazepine38$6,663
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine16$6,642
DilantinPhenytoin Sodium Extended12$3,822
Gabapentin93$3,130
Zonisamide19$2,783
Divalproex Sodium ErDivalproex Sodium20$2,717
Carbidopa-LevodopaCarbidopa/Levodopa57$2,319
Lacosamide20$2,215
Entacapone15$2,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$29$60,48320 claims
AbbVieQulipta$1,835$24,83116 claims
SK Life Science, Inc.Xcopri$386$22,69315 claims
Avanir Pharmaceuticals, Inc.Nuedexta$49$20,49313 claims
PfizerDilantin$162$3,82212 claims
Upsher-smith Laboratories LLCTopiramate$41$58644 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$59$52311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →